{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"PFS was defined as the time from study enrollment (for non-randomized cohorts)/ the time from randomization (for randomized cohorts) to the first observation of progressive disease (PD) overall response or death without documented disease progression per RECIST V1.1 criteria.","groups":[{"description":"Participants received high dose LY3499446 as oral monotherapy BID in 21-day cycles.","id":"OG000","title":"LY3499446 Phase 1 Cohort A1 (High Dose)"},{"description":"Participant received mid dose LY3499446 as oral monotherapy QOD in 21-day cycles.","id":"OG001","title":"LY3499446 Phase 1 Cohort AO (Mid Dose)"},{"description":"Participants received low dose LY3499446 as oral monotherapy QD in 21-day cycles in 21-day cycles.","id":"OG002","title":"LY3499446 Phase 1 Cohort A-2 (Low Dose)"}],"populationDescription":"Zero participants were analyzed due to early termination of study.","reportingStatus":"POSTED","timeFrame":"Baseline to Objective Progression or Death Due to Any Cause (Up to 11 Months)","title":"Phase 1: PFS","type":"SECONDARY"}